CURRICULUM VITAE
NAME: DWOMOA ADU
DATE OF BIRTH: 15th August 1945
| QUALIFICATIONS: | Year Conferred |
| BA Cambridge | 1966 |
| MA Cambridge | 1970 |
| MB,B Chir Cambridge | 1969 |
| MD Cambridge | 1981 |
| FRCP London | 1986 |
ACCREDITATION:
1981 Accreditation in General (Internal) Medicine and Renal Disease
| PRESENT APPOINTMENTS: |
| Consultant Nephrologist, Queen Elizabeth Hospital Birmingham and Senior Clinical Lecturer, University of Birmingham |
| PREVIOUS APPOINTMENTS: |
| Senior Registrar Guys Hospital 1980-1981 Research Registrar Guys Hospital 1978-1981 Lecturer University of Ghana Medical School 1973-1978 |
PERSONAL RESUME:
Chairman: Renal Specialist Advisory Committee 2000-2002 (National Nephrology Training Committee)
Regional and Continuing Professional Advisor: Royal College of Physicians 1999-2003
President: Section of Nephrology. Royal Society of Medicine 2000- 2002
Council member: Royal College of Physicians 2003-2005
Chairman: Renal Association Clinical Trials Committee 1993-2000.
Member: Africa Subcommittee of ISN COMGAN: Current
I have had a particular interest in postgraduate education in Nephrology having served as Chairman of the United Kingdom Nephrology Training Committee. In addition I have served as Regional Adviser and elected Councillor of the Royal College of Physicians of London, serve on the Council of the Kings Fund (a health policy organization) and was Chairman of the Renal Association Clinical Trials Committee
RESEARCH:
My clinical research is oriented towards assessing disease activity and damage in patients with lupus nephritis and vasculitis and developing clinical trials of therapy. We developed the Birmingham Vasculitis activity Index and Vascular Damage Index and these are recognised internationally as the gold standard methods. Clinical trials in vasculitis that I lead or participated in have defined improved ways of treating vasculitis and lupus nephritis. A second strand of my research has been on the immunopathogenesis of vasculitis. These studies have helped define mechanisms of disease which in turn arre leading to novel therapies e.g. anti-TNF antibodies. Our immunogenetic studies now seek to define the genetic basis for damage in the vasculitides.
| RECENT PUBLICATIONS: |
| Tse WY, Nash GB, Hewins P, Savage CO, Adu D. ANCA-induced neutrophil F-actin polymerization: implications for microvascular inflammation. Kidney Int 2005;67:130-9. |
| Stirling CM, Mathieson P, Boulton-Jones JM, Feehally J, Jayne D, Murray HM, et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. Qjm 2005;98:443-9. Epub 2005 May 6. |
| Pankhurst T, Howie AJ, Adu D, DM AW, Lipkin GW. Incidental neoplasms in renal biopsies. Nephrol Dial Transplant 2005;4:4. |
| Howie AJ, Pankhurst T, Sarioglu S, Turhan N, Adu D. Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion. Kidney Int 2005;67(3):987-1001. |
| Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004;63:525-9. |
| Pankhurst T, Adu D. Antibodies in the prevention of renal allograft rejection. Expert Opin Biol Ther 2004;4:243-52. |
| Howie AJ, Ferreira MA, Lipkin GW, Adu D. Measurement of chronic damage in the donor kidney and graft survival. Transplantation 2004;77:1058-65. |
| Holland M, Hewins P, Goodall M, Adu D, Jefferis R, Savage CO. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol 2004;138:183-92. |
| Anton C, Nightingale PG, Adu D, Lipkin G, Ferner RE. Improving prescribing using a rule based prescribing system. Qual Saf Health Care 2004;13:186-90. |
| Howie AJ, Turhan N, Adu D. Powerful morphometric indicator of prognosis in lupus nephritis. Qjm 2003;96:411-20. |
| Elmedhem A, Adu D, Savage CO. Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 2003;18:1001-4. |
| Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. Bmj 2003;326(7393):789. |
| Holland M, Takada K, Okumoto T, Takahashi N, Kato K, Adu D, et al. Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis. Clin Exp Immunol 2002;129:183-90. |
| Day CJ, Cockwell P, Lipkin GW, Savage CO, Howie AJ, Adu D. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002;17:2011-3. |
| Bacon PA, Adu D. Microscopic polyangiitis: Clinical Aspects. In: Hoffman GS, Weyand CM, editors. Inflammatory Diseases of Blood Vessels. New York: Basel: Marcel Dekker, Inc, 2002:355-363. |
| Tse WY, Adu D. Non-steroidal anti-inflammatory drugs and the kidney. In: Adu D, Emery P, Madaio M, editors. Rheumatology and the Kidney. Oxford: Oxford University Press, 2001:415-430. |
| Tse WY, Williams J, Pall A, Wilkes M, Savage CO, Adu D. Antineutrophil cytoplasm antibody-induced neutrophil nitric oxide production is nitric oxide synthase independent. Kidney International 2001;59:593-600. |
| Howie AJ, Ferreira MA, Adu D. Prognostic value of simple measurement of chronic damage in renal biopsy specimens. Nephrology Dialysis Transplantation 2001;16:1163-9. |
| Harper L, Radford D, Plant T, Drayson M, Adu D, Savage CO. IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients. Arthritis & Rheumatism 2001;44:921-30. |
| Harper L, Cockwell P, Adu D, Savage CO. Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney International 2001;59:1729-38. |
| de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant.. 2001;16:2018-27. |
| Adu D, Emery P, Madaio M, editors. Rheumatology and the kidney. Oxford: Oxford University Press, 2001. |
| Adu D, Tse WY. Rheumatoid arthritis, mixed connective tissue disease, and polymyositis. In: Adu D, Emery P, Madaio M, editors. Rheumatology and the kidney. Oxford: Oxford University Press, 2001:293-302. |
| Adu D, Bacon PA. Microscopic polyangiitis: Clinical aspects. In: Hoffman GS, Weyand CM, editors. Inflammatory disease of blood vessels. New York: Marcel Dekker, Inc, 2001. |
| Adu D, Howie AJ, W.Y. T. Clinical Investigation. In: Schena FP, Davison AM, Grunfeld J-P, Valderrabano F, van der Woude FJ, editors. Nehrology: Clinical Medicine Series. London: McGraw-Hill International, 2001:17-32. |
| Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001;10:203-8. Adu D. The evidence base for the treatment of lupus nephritis in the new millennium. Nephrology Dialysis Transplantation 2001;16:1536-8. |